Search - tctmd.com

Displaying 41 - 60 of 61

Sort: Relevancy | Date

Presentation TCT 2015

Cangrelor + Bivalirudin: The Perfect Marriage or a Forced Union?

Presenter: John A. Bittl, Robert A. Harrington, Harvey D. White

October 12, 2015

Presentation TCT 2015

Debate 1: Should Cangrelor or an Oral ADP Antagonist Be Used in Most STEMI Patients? Prasugrel for Primary PCI Is Simplest and Best!

Presenter: C. Michael Gibson, Marco Valgimigli, Sigmund Silber

October 11, 2015

Presentation TCT 2015

Debate 1: Should Cangrelor or an Oral ADP Antagonist Be Used in Most STEMI Patients? Oral or Crushed Ticagrelor for All!

Presenter: C. Michael Gibson, Marco Valgimigli, Guido Parodi

October 11, 2015

Presentation TCT 2015

Debate 1: Should Cangrelor or an Oral ADP Antagonist Be Used in Most STEMI Patients? The Mechanism and Data Support Cangrelor!

Presenter: C. Michael Gibson, Marco Valgimigli, Harvey D. White

October 11, 2015

News Conference News TCT 2015

Experts Debate Optimal Pharmacologic Approach for STEMI Patients

October 11, 2015

Presentation TCT 2014

TCT 482: Effect of Cangrelor on Ischemic Endpoints: Further Analyses From CHAMPION PHOENIX

Presenter: John M. Lasala, Stuart J. Pocock, Deepak L. Bhatt

September 16, 2014

Presentation TCT 2014

Effect of Cangrelor on Ischemic Endpoints: Further Analyses from CHAMPION PHOENIX

Presenter: Deepak Bhatt

September 16, 2014

Presentation TCT 2014

Definitely To Prevent Stent Thrombosis and MI!

Presenter: Gregg W. Stone

September 15, 2014

Presentation TCT 2014

Definitely Not An Expensive Way to Increase Bleeding Without Much Benefit!

Presenter: Nick Curzen

September 15, 2014

Presentation TCT 2014

Cangrelor III: Detailed Effects on Intraprocedural and Postprocedural Stent Thrombosis

Presenter: Christian W. Hamm, Franz-Josef Neumann, Philippe Généreux

September 15, 2014

Presentation TCT 2014

Cangrelor II: New Data from the FDA Advisory Board Panel

Presenter: Christian W. Hamm, Franz-Josef Neumann, Philippe Généreux, Robert A. Harrington

September 15, 2014

Presentation TCT 2014

Cangrelor I: Data Essentials from the Champion Trials

Presenter: Christian W. Hamm, Franz-Josef Neumann, Philippe Généreux, Deepak L. Bhatt

September 15, 2014

Presentation TCT 2014

NO: Cangrelor Is No Champion Next to the Appropriate Use of Potent Oral Antiplatelet Agents!

Presenter: Dimitrios Alexopoulos

September 14, 2014

Presentation TCT 2013

I'm Sure: Cangrelor Is Required In Addition!

Presenter: Gregg Stone

October 31, 2013

Presentation TCT 2013

Cangrelor Will Be the Answer for Most in the Acute Setting!

Presenter: Robert Harrington

October 31, 2013

Presentation TCT 2013

Cangrelor Properties: PK, PD and More

Presenter: Sergio Leonardi

October 31, 2013

Presentation TCT 2013

The Case for Intravenous Cangrelor as the Preferred ADP Antagonist to Support Primary PCI

Presenter: Deepak Bhatt

October 30, 2013

News Conference News TCT 2013

EUROMAX: Prehospital Bivalirudin Reduces Bleeding in STEMI

October 30, 2013

News Conference News TCT 2013

Intraprocedural ST Predicts Adverse Short-Term Events

October 29, 2013

Presentation TCT 2012

Cangrelor: CHAMPION PHOENIX Update

Presenter: Harvey White

October 24, 2012

Advertisement

Cangrelor + Bivalirudin: The Perfect Marriage or a Forced Union?

Debate 1: Should Cangrelor or an Oral ADP Antagonist Be Used in Most STEMI Patients? Prasugrel for Primary PCI Is Simplest and Best!

Debate 1: Should Cangrelor or an Oral ADP Antagonist Be Used in Most STEMI Patients? Oral or Crushed Ticagrelor for All!

Debate 1: Should Cangrelor or an Oral ADP Antagonist Be Used in Most STEMI Patients? The Mechanism and Data Support Cangrelor!

Experts Debate Optimal Pharmacologic Approach for STEMI Patients

TCT 482: Effect of Cangrelor on Ischemic Endpoints: Further Analyses From CHAMPION PHOENIX

Effect of Cangrelor on Ischemic Endpoints: Further Analyses from CHAMPION PHOENIX

Definitely To Prevent Stent Thrombosis and MI!

Definitely Not An Expensive Way to Increase Bleeding Without Much Benefit!

Cangrelor III: Detailed Effects on Intraprocedural and Postprocedural Stent Thrombosis

Cangrelor II: New Data from the FDA Advisory Board Panel

Cangrelor I: Data Essentials from the Champion Trials

NO: Cangrelor Is No Champion Next to the Appropriate Use of Potent Oral Antiplatelet Agents!

I'm Sure: Cangrelor Is Required In Addition!

Cangrelor Will Be the Answer for Most in the Acute Setting!

Cangrelor Properties: PK, PD and More

The Case for Intravenous Cangrelor as the Preferred ADP Antagonist to Support Primary PCI

EUROMAX: Prehospital Bivalirudin Reduces Bleeding in STEMI

Intraprocedural ST Predicts Adverse Short-Term Events

Cangrelor: CHAMPION PHOENIX Update

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content